# Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
Canonical URL: https://biopharmsignal.com/news/KRYS/krystal-biotech-to-report-second-quarter-2026-financial-results-on-august-3-2026-2f96b902
Ticker: KRYS
Company: Krystal Biotech
Source: Krystal Biotech
Published: 2026-07-23 21:00 EST
## Summary

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter...

## Article Body
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August 3, 2026, prior to the open of U.S. markets.

The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, August 3, 2026, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/54300 .

For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.com .

About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK ® , the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit www.krystalbio.com to learn more or follow us on LinkedIn and X .

CONTACT Investors and Media: Stéphane Paquette, PhD Krystal Biotech spaquette@krystalbio.com
## Recent Company News
- 2026-07-23 21:00 EST — [Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026](https://biopharmsignal.com/news/KRYS/krystal-biotech-to-report-second-quarter-2026-financial-results-on-august-3-2026-2f96b902) — Source: Krystal Biotech
- 2026-05-18 12:00 EST — [Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa](https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-united-kingdom-mhra-approval-of-vyjuvek-for-the-treatm-23d2eafe) — Source: Krystal Biotech
- 2026-05-07 12:00 EST — [Krystal Biotech to Present at BofA Securities 2026 Health Care Conference](https://biopharmsignal.com/news/KRYS/krystal-biotech-to-present-at-bofa-securities-2026-health-care-conference-f4e6ec6b) — Source: Krystal Biotech
- 2026-05-04 11:00 EST — [Krystal Biotech Announces First Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-first-quarter-2026-financial-and-operating-results-9aa0ae94) — Source: Krystal Biotech
- 2026-04-30 12:00 EST — [Krystal Biotech to Present at Upcoming Scientific Conferences](https://biopharmsignal.com/news/KRYS/krystal-biotech-to-present-at-upcoming-scientific-conferences-5a0d2417) — Source: Krystal Biotech
## Related News
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)
- 2026-07-28 12:05 EST — GSK — [GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK](https://biopharmsignal.com/news/GSK/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-6f2bb859)